jRCT1030260022招募中不适用
An observational study on the safety and therapeutic effects of oral administration of SPP in subjects with aging symptoms
未提供0 个研究点目标入组 10 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •1.Male or female aged 20 years or older at the time of informed consent.
- •2.Individuals who complain of aging symptoms, such as physical decline or chronic fatigue.
- •3.Individuals who fully understand the study and provide written voluntary informed consent.
排除标准
- •Patients who were unable to continue treatment due to hypersensitivity or allergic reactions to SPP.
- •Patients who are taking other medications concomitantly, or who have previously participated in clinical trials and have not yet taken the study drug for at least one month.
- •Patients who are otherwise deemed inappropriate by the principal investigator or co-investigator.
研究者
相似试验
招募中
不适用
An observational study on the safety and therapeutic effects of oral administration of Quercefit in subjects with aging symptomsAge-related decline in physical function and aging-associated symptomsjRCT103026001810
招募中
不适用
An observational study on the safety and therapeutic effects of oral administration of NMN to subjects complaining of aging symptomsAge-related symptoms (e.g., fatigue, decreased concentration, sleep disturbance)jRCT103026002010
招募中
不适用
An observational study on the safety and efficacy of oral administration of 5-deazaflavin TND1128 in subjects with symptoms of agingAge-related symptoms (e.g., fatigue, decreased concentration, sleep disturbance)jRCT103026001910
招募中
2 期
A study to investigate the safety and clinical activity of belantamab for the treatment of multiple myeloma when used as monotherapy and in combination treatments.Multiple myeloma2022-501941-63-00Glaxosmithkline Research & Development Limited3
招募中
1 期
A clinical study to investigate the safety, tolerability and pharmacokinetic profile of single ascending concentrations of OPT101 in peritoneal dialysis patients.Chronic kidney disease2025-522966-61-00OPTERION Health AG12